Search:

Product Information All Elsevier Sites   Advanced Product Search
SiteStat.jsp
RECENT PROGRESS IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA, AN ISSUE OF HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA, 23-5
Recent Progress in the Treatment of Acute Lymphoblastic Leukemia, An Issue of Hematology/Oncology Clinics of North America, 23-5
To order this title, and for more information, click here

By
Wendy Stock, MD
Meir Wetzler, MD

Included in series
The Clinics: Internal Medicine,

Description
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2-5 years. Although a few cases are associated with inherited genetic syndromes, the cause of ALL remains largely unknown. This issue presents articles that discuss current thinking on the diagnosis and treatment of the disease. Articles specifically emphasize molecular genetics, allogeneic stem cell transplantation, and treatments including, clofarabine, nelarabine, rituximab, and PegAsp.

Bibliographic details
Hardbound, 0 pages, publication date: NOV-2009
ISBN-13: 978-1-4377-1227-8
ISBN-10: 1-4377-1227-4
Imprint: SAUNDERS


041/407
Last update: 30 Oct 2009
Reviews
Submit your review
Bookmark this page
Recommend this publication
Overview of all books
Printer-friendly version   Printer-friendly version